Study Location | Year | N | CQ Efficacy | SP Efficacy | CQ + SP Efficacy | Endpoint in Days | Comparison of CQ+SP vs. CQ, CQ+SP vs. SP | Reference |
---|---|---|---|---|---|---|---|---|
Nigeria | 2004 | 153 | n/a | n/a | 90% | 28 | n/a | [30] |
Laos | 2003 | 110 | n/a | n/a | 93% | 42 | n/a n/a | [14] |
Bangladesh | 2002 | 133 | n/a | n/a | 72% | 28 | n/a | [18] |
Eastern Uganda | 2002 | 280 | n/a | 42% | 60% | 28 | n/a p = ns | [21] |
Southern Uganda | 2002 | 448 | n/a | 70% | 83% | 14 | n/a p < 0.001 | [12] |
Western Uganda | 2001 | 141 | 93% | 100% | 100% | 14 | p = ns p = ns | [13] |
Southern Laos | 2001 | 119 | 55% | 82% | 83% | 14 | p = 0.029 p = ns | [19] |
Papua, Indonesia | 1999 | 169 | 17% | 79% | 62% | 28 | p < 0.001 p = 0.047 | [17] |
Southwest Nigeria | 1999 | 111 | 93% | n/a | 96% | 28 | n/a p = ns | [22] |
Papua New Guinea | 1998–1999 | 513* | n/a | n/a | 95% | 28 | n/a | [3] |
The Gambia | 1995 | 405 | n/a | 90% | 95% | 28 | n/a p = ns | [20] |
Mumbai, India | N/a | 49 | 36% | n/a | 87% | 42 | p < 0.026 n/a | [2] |